Overview
Indications
Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to absta
Contraindications
When this intervention should not be used
Naltrexone is contraindicated in: PRECAUTIONS Patients receiving opioid analgesics (see). WARNINGS Patients with current physiologic opioid dependence (see). WARNINGS Patients in acute opiate withdrawal (see). Any individual who has failed the naloxone challenge test or has a positive urine screen f
Indications & Related Conditions
Conditions associated via SNOMED clinical relationships
Administration & Protocol
Dosing, route, and treatment protocol
Detailed dosage and administration information is available in the full FDA drug label.
View full prescribing information on DailyMedMonitoring & Follow-Up
Biomarkers relevant to this intervention via related conditions
No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.
Clinical Trials
55 trials linked to this intervention
Recent Trials
Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses
A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet
Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity
Low Dose Naltrexone for Pain in Patients With HIV
Research Evidence
Published studies and systematic reviews
Research data from MEDLINE/PubMed
Benefits & Expected Outcomes
Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.
Risks & Side Effects
Adverse reaction and safety data for this drug is sourced from the FDA-approved label.
View adverse reactions & drug interactions on DailyMedRelated Symptoms
Symptoms associated with conditions this intervention addresses
No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.
Alternatives & Comparisons
Alternative treatments, comparison data, and clinical decision support are pending physician authorship.
This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.
Do not start, stop, or change any treatment without consulting your healthcare provider.
Quick Facts
- Type
- Substance / Medication
- Fully Specified Name
- Naltrexone (substance)
- SNOMED CT
- 373546002
- UMLS CUI
- C0027360
- RxNorm CUI
- 7243
- Labeler
- Complete Pharmacy and Medical Solutions
Clinical Data
This intervention maps to 3 entities in the Ltrl knowledge graph.
Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.